dostarlimab
gsk
['rectal', 'dostarlimab']
absolutely unbelievable data by at #asco2022: 100% cr rate in 14 consecutive high risk (90%+st3) rectal cancer pts w/ dostarlimab pd1 monotherapy. no patient required chemo/surgery/rt. #immunoablative therapy is here + published now in 
Medonc Fellow+Rising GI Onc Faculty @MSKCancerCenter | Former @BrighamMedRes @harvardmed Resident | Translational Scientist in Diaz lab | #AnimalLover #uncfan